Drug Type Chemical drugs |
Synonyms SPESN38-5 |
Target |
Action inhibitors |
Mechanism TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Application |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | IND Application | United States | 17 Nov 2022 | |
| Neoplasms | IND Application | United States | 17 Nov 2022 | |
| Neoplasms | IND Application | United States | 17 Nov 2022 | |
| Colorectal Cancer | Preclinical | United States | 10 Dec 2023 | |
| Colorectal Cancer | Preclinical | United States | 10 Dec 2023 | |
| Soft Tissue Sarcoma | Preclinical | United States | 10 Dec 2023 | |
| Soft Tissue Sarcoma | Preclinical | United States | 10 Dec 2023 |





